NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass. April 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. In addition to the positive clinical outcomes, the study also demonstrated a positive trend toward impact on Neurofilament (NfL) levels. The presentation, titled, "PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary and Secondary Endpoints in the Phase 2b PARADIGM Trial," was presented yesterday as an Emerging Science presentation by Merit Cudkowicz, M.D., M.Sc., chair of neurology and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. The study showed that PrimeC, a novel formulation of
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseasePR Newswire
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingPR Newswire
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 [Yahoo! Finance]Yahoo! Finance
- NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024PR Newswire
NRSN
Sec Filings
- 4/25/24 - Form D
- 4/12/24 - Form 424B5
- 4/12/24 - Form 6-K
- NRSN's page on the SEC website